Endo, Inc., a leading specialty pharmaceutical enterprise, has secured approval from the US Food and Drug Administration (FDA) to commence the commercial production of Vasostrict (vasopressin injection, USP) at their latest state-of-the-art aseptic manufacturing plant in Indore, India. Spanning over 20,000 square feet, this facility significantly boosts Endo’s capability in sterile injectable production and enhances growth prospects for its Injectable Solutions division.
“Achieving this step is a major advancement for Endo, underscoring our dedication to investment and innovation within the sterile injectables sector,” explained Scott Hirsch, Endo’s Interim CEO. “The FDA endorsement of our cutting-edge production site marks a pivotal effort to fulfill product demands while ensuring patients receive top-quality medications.”
Purpose-built for the aseptic production of sterile injectables, the Indore site is set to undertake the intricate and highly-specialized task of manufacturing these pharmaceutical products. Future plans entail the facility crafting medications in syringe form, in addition to vial production.
This is the inaugural US FDA endorsement for the Indore location. Moving forward, Endo intends to seek authorization for more products at this facility, with expectations that production will officially kick off in 2026.
As a dynamic specialty pharmaceutical company, Endo is committed to transforming insights into therapies that enhance and improve lives.